Picture this: a huge house is being guarded by multiple security guards. Now imagine your body is that house, and the ...

Signs that Amgen was cooling on rocatinlimab emerged last year. Asked about the market positioning of the antibody at a Citi ...

The Union Budget presented by Finance Minister Nirmala Sitharaman in Parliament on Sunday on healthcare and pharmaceuticals ...

The Union Budget 2026 highlights India’s growing burden of diabetes, obesity and cancer. In her speech, Finance Minister ...

The next major drugmaker interested in what Repertoire has to offer is Eli Lilly, which has thrown down $85 million upfront and floated up to $1.84 billion more in biobucks to collaborate on potential ...

The decision comes more than a year after disappointing initial Phase 3 results and casts further doubt on a class of ...

The Union Budget 2026 maintains policy continuity but boosts defence, railways, semiconductors, biosimilars, and rare earth sectors.

A reanalysis of twin data from Denmark and Sweden suggests that how long we live now depends roughly equally on the genes we ...

Advanced Integrated Health highlights a root-cause approach to care, helping patients address lifestyle-driven chronic ...

Dr. Stuart Himmelstein, DC, a Philadelphia-based chiropractor, examines how peripheral neuropathy is evaluated in ...

Amgen ends its rocatinlimab partnership, returning control to Kyowa Kirin, citing strategy changes, weaker Phase 3 results ...

Cash-rich Cullinan Therapeutics stock: zipalertinib NDA in Q1 2026 plus CLN-978 and CLN-049 AML catalysts. Read here for more analysis.